Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;71(9):e31131.
doi: 10.1002/pbc.31131. Epub 2024 Jun 20.

Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review

Shaikha Alqahtani  1 , Karen DiValerio Gibbs  2 , Natalie A Montanez  3 , Kate J Krause  4 , C Heleen van Ommen  5 , Lakshmi V Srivaths  1   3
Affiliations

Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review

Shaikha Alqahtani et al. Pediatr Blood Cancer. 2024 Sep.

Abstract

Adolescent venous thromboembolism (VTE) has unique challenges in management, complications, and compliance to anticoagulants. Direct oral anticoagulants (DOACs) have been approved for pediatric VTE management, with an increasing use especially in adolescents. Primary objective is to evaluate the safety and efficacy of DOAC therapy in adolescent VTE. Secondary objectives include adverse events, bleeding events, and overall mortality. A SR protocol was registered in PROSPERO 2022 (CRD42022363928). Databases were searched from inception to September 22, 2022. Studies with children aged 10-18 years, VTE diagnosis, DOAC therapy, randomized control trials (RCTs), cohort, and relevant study types were included. Studies including prophylaxis, non-DOAC therapy, arterial thrombosis, age outliers, non-relevant study types were excluded. Findings are reported in accordance to PRISMA 2020. Nine reports from five studies, published between 2016 and 2022, were included. Rivaroxaban was the most common DOAC. VTE recurrence was 0.02% in the rivaroxaban phase III trial and one patient in the dabigatran phase IIb/III trial. Complete/partial thrombus resolution (CR/PR) was 76.6% in the rivaroxaban phase III trial, and 83.9% in the dabigatran phase IIb/III trial. CR/PR was found to be 68.4% in Dhaliwal et al. study and 83.3% in Hassan et al. study. Major bleeding occurred in one patient. Headache and gastrointestinal symptoms were commonly seen. All-cause mortality occurred in a patient due to cancer progression. DOAC therapy in adolescent VTE had CR/PR in two-thirds of the patients, with low incidence of VTE recurrence and major bleeding. As there are only two randomized controlled trial (RCTs), future adolescents' studies are required to validate our results.

Keywords: adolescent; direct oral anticoagulant; systematic review; venous thromboembolism.

PubMed Disclaimer

References

REFERENCES

    1. O'Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism across US children's hospitals. Pediatrics. 2022;149(3):e2021054649.
    1. Raffini L, Huang Y‐S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001‐1008.
    1. Jung HL. Venous thromboembolism in children and adolescents. Blood Res. 2016;51(3):149‐151.
    1. Chen J, Bi G, Wu F, Qin X. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism. Pediatr Res. 2022;93(6):1491‐1498.
    1. Whitworth H, Raffini L. Practical considerations for use of direct oral anticoagulants in children. Front Pediatr. 2022;10:860369.

Publication types